This analysis performed in the BEVERLY-2 phase II trial identified MMP2 and MMP9 as candidate biomarkers correlated consistently to DFS and OS in patients with HER2-positive inflammatory breast cancer. Here, ERBB2 is linked to inflammatory breast carcinoma.